Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk.

Estrogen receptor (ER) and androgen receptor (AR) may be expressed in thyroid tumors, but their prognostic role is controversial. We investigated whether ER and AR expressions could confer a more aggressive phenotype to thyroid tumors. We enrolled 91 patients (13 males and 78 females, mean age 49.3±14.8 years) bearing small (T1 in the 2006 TNM system) differentiated thyroid cancers (DTC). Thirty-eight tumors were incidental histological findings. Using immunohistochemistry, we evaluated ERα, ERβ, and AR expressions in tumors and in its correspondent extra-tumor parenchyma. In tumors, 13 (16.7%) women and one (7.7%) man expressed ERα; 42 (53.8%) women and six (46%) men expressed ERβ; and 16 (20.5%) women and three (23.1%) men expressed AR. In normal thyroid parenchymas, ERβ was expressed in 52 (66.7%) women and nine (69.2%) men, ERα in three (3.8%) women, and AR in 13 (16.7%) women. Compared with normal thyroid parenchyma, tumors gained ERα and lost ERβ expressions. Incidental cancers were more commonly ERα(-) than ERα(+) (47.7 vs 14.3%, P=0.037). Postsurgical serum thyroglobulin was higher in ERα(+) tumors than in the ERα(-) tumors (P=0.04). ERβ(-) tumors showed vascular invasion more frequently than the ERβ(+) tumors (26.2 vs 4.1%, P=0.005). AR(+) tumors showed capsular invasion more frequently than the AR(-) tumors (77.8 vs 46.6%, P=0.014). In conclusion, ERα positivity, ERβ negativity, and AR expressions are associated with a more aggressive phenotype of small T1-DTC. ER and AR expressions may represent an additional criterion in deciding whether to perform radioiodine ablation in these tumors.

[1]  S. Banu,et al.  Androgen receptor expression in human thyroid cancer tissues: A potential mechanism underlying the gender bias in the incidence of thyroid cancers , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  A. Carpi,et al.  Estrogen activity as a preventive and therapeutic target in thyroid cancer. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  M. Barone,et al.  Dietary, Endocrine, and Metabolic Factors in the Development of Colorectal Cancer , 2012, Journal of Gastrointestinal Cancer.

[4]  S. Asa,et al.  Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation , 2011, Modern Pathology.

[5]  M. Schlumberger,et al.  Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. , 2011, The Journal of clinical endocrinology and metabolism.

[6]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[7]  R. Tiwari,et al.  Metastatic phenotype is regulated by estrogen in thyroid cells. , 2010, Thyroid : official journal of the American Thyroid Association.

[8]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[9]  V. Mittal,et al.  Expression of Estrogen Receptor, Progesterone Receptor, and Vascular Endothelial Growth Factor-A in Thyroid Cancer , 2009, The American surgeon.

[10]  S. Matsuda,et al.  Reproductive and menstrual factors and thyroid cancer among Japanese women: the Japan Collaborative Cohort Study. , 2009, Journal of women's health.

[11]  I. Reccia,et al.  Risk Factors for Nodal Metastasis and Recurrence Among Patients with Papillary Thyroid Microcarcinoma: Differences in Clinical Relevance Between Nonincidental and Incidental Tumors , 2009, World Journal of Surgery.

[12]  M. Shupnik,et al.  ERβ in breast cancer—Onlooker, passive player, or active protector? , 2008, Steroids.

[13]  S. Badve,et al.  Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications , 2008, Journal of Clinical Pathology.

[14]  G. Chen,et al.  Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. , 2008, Current cancer drug targets.

[15]  Q. Zeng,et al.  The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas , 2007, The Journal of pathology.

[16]  Q. Zeng,et al.  Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor – ERK pathway , 2007, Cell proliferation.

[17]  B. Larijani,et al.  Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. , 2007, Singapore medical journal.

[18]  R. Kloos,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[19]  G. Chen,et al.  Induction of Thyroid Papillary Carcinoma Cell Proliferation by Estrogen Is Associated with an Altered Expression of Bcl‐xL , 2005, Cancer journal.

[20]  P. Pujol,et al.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. , 2004, Endocrine-related cancer.

[21]  A. Belfiore,et al.  Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. , 2004, The Journal of clinical endocrinology and metabolism.

[22]  R. Clarke,et al.  Steroid receptors and proliferation in the human breast , 2003, Steroids.

[23]  T. Simoncini,et al.  Non-genomic actions of sex steroid hormones. , 2003, European journal of endocrinology.

[24]  S. Banu,et al.  Testosterone and estradiol differentially regulate TSH-induced thyrocyte proliferation in immature and adult rats , 2002, Steroids.

[25]  C. Hsueh,et al.  Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas , 2002, Journal of surgical oncology.

[26]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[27]  L. Bernstein,et al.  Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  Raj Kumar,et al.  The structure of the nuclear hormone receptors , 1999, Steroids.

[29]  E. Negri,et al.  A pooled analysis of case-control studies of thyroid cancer ¶II. Menstrual and reproductive factors , 1999, Cancer Causes & Control.

[30]  C. Schairer,et al.  Cancer incidence and mortality in women receiving estrogen and estrogen‐progestin replacement therapy—long‐term follow‐up of a Swedish cohort , 1996, International journal of cancer.

[31]  D. Rades,et al.  The prognostic impact of tumor cell expression of estrogen receptor‐α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer , 2012, Cancer.

[32]  Raj Kumar,et al.  Steroid hormone receptors in cancer development: a target for cancer therapeutics. , 2011, Cancer letters.

[33]  D. Dazzi,et al.  Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. , 2010, European journal of endocrinology.

[34]  B. O’Malley,et al.  Modulation of steroid hormone receptor activity. , 2010, Progress in brain research.

[35]  L. Ceriani,et al.  Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. , 2007, Clinical chemistry and laboratory medicine.

[36]  R. Lloyd,et al.  Androgen receptor expression in C-cells and in medullary thyroid carcinoma , 2003, Endocrine pathology.

[37]  P. Govindarajulu,et al.  Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action , 2001, Endocrine pathology.

[38]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[39]  M. Derwahl,et al.  Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. , 2001, The Journal of clinical endocrinology and metabolism.